New liver drug safety trial begins for hepatitis b scarring

NCT ID NCT07343778

Completed Disease control Sponsor: Beijing Continent Pharmaceutical Co, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study tests a drug called hydronidone in 300 adults with liver scarring (fibrosis or cirrhosis) from chronic hepatitis B. Participants take the drug three times daily for 28 days to see if it is safe. The main goal is to track any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hydronidone capsules
What this could lead to: If successful, this could show that hydronidone is safe enough to move forward in treating liver scarring from hepatitis B.
What could go wrong: This is an early safety study with no placebo group, so it cannot prove the drug works. Side effects may still emerge in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B WITH HEPATIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection cirrhosis of liver fibrotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B WITH HEPATIC FIBROSIS

Contacts and locations

Locations

The Sixth People's Hospital of Zhengzhou City

Zhengzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.